Tags

Type your tag names separated by a space and hit enter

Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014.
Alzheimers Dement. 2015 Jul; 11(7):865-84.AD

Abstract

INTRODUCTION

The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials.

METHODS

We searched for ADNI publications using established methods.

RESULTS

ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis.

DISCUSSION

ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

Links

PMC Free PDF

Authors+Show Affiliations

Weiner MW
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA; Department of Radiology, University of California, San Francisco, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Department of Psychiatry, University of California, San Francisco, San Francisco, CA, USA; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA. Electronic address: michael.weiner@ucsf.edu.
Veitch DP
Department of Veterans Affairs Medical Center, Center for Imaging of Neurodegenerative Diseases, San Francisco, CA, USA.
Aisen PS
Department of Neurosciences, University of California- San Diego, La Jolla, CA, USA.
Beckett LA
Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, Davis, CA, USA.
Cairns NJ
Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, Saint Louis, MO, USA; Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
Cedarbaum J
Neurology Early Clinical Development, Biogen Idec, Cambridge, MA, USA.
Donohue MC
Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California, San Diego, San Diego, CA, USA.
Green RC
Division of Genetics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Harvey D
Division of Biostatistics, Department of Public Health Sciences, University of California, Davis, Davis, CA, USA.
Jack CR
Department of Radiology, Mayo Clinic, Rochester, MN, USA.
Jagust W
Helen Wills Neuroscience Institute and the School of Public Health, University of California Berkeley, Berkeley, CA, USA.
Morris JC
Department of Neurology, Washington University School of Medicine, Saint Louis, MO, USA.
Petersen RC
Department of Neurology, Mayo Clinic, Rochester, MN, USA.
Saykin AJ
Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA.
Shaw L
Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Thompson PM
Imaging Genetics Center, Institute for Neuroimaging and Informatics, University of Southern California, Marina Del Rey, CA, USA.
Toga AW
Laboratory of Neuroimaging, Institute of Neuroimaging and Informatics, Keck School of Medicine of University of Southern California Los Angeles, CA, USA.
Trojanowski JQ
Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Research, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Institute on Aging, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Alzheimer's Disease Core Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Udall Parkinson's Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alzheimer's Disease Neuroimaging Initiative
No affiliation info available

MeSH

Alzheimer DiseaseBiomarkersClinical Trials as TopicDatabases, BibliographicDisease ProgressionHumansLongitudinal StudiesNeuroimaging

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural
Review

Language

eng

PubMed ID

26194320

Citation

Weiner, Michael W., et al. "Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014." Alzheimer's & Dementia : the Journal of the Alzheimer's Association, vol. 11, no. 7, 2015, pp. 865-84.
Weiner MW, Veitch DP, Aisen PS, et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement. 2015;11(7):865-84.
Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Donohue, M. C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., Petersen, R. C., Saykin, A. J., Shaw, L., Thompson, P. M., Toga, A. W., & Trojanowski, J. Q. (2015). Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's & Dementia : the Journal of the Alzheimer's Association, 11(7), 865-84. https://doi.org/10.1016/j.jalz.2015.04.005
Weiner MW, et al. Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimers Dement. 2015;11(7):865-84. PubMed PMID: 26194320.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. AU - Weiner,Michael W, AU - Veitch,Dallas P, AU - Aisen,Paul S, AU - Beckett,Laurel A, AU - Cairns,Nigel J, AU - Cedarbaum,Jesse, AU - Donohue,Michael C, AU - Green,Robert C, AU - Harvey,Danielle, AU - Jack,Clifford R,Jr AU - Jagust,William, AU - Morris,John C, AU - Petersen,Ronald C, AU - Saykin,Andrew J, AU - Shaw,Leslie, AU - Thompson,Paul M, AU - Toga,Arthur W, AU - Trojanowski,John Q, AU - ,, PY - 2014/12/12/received PY - 2015/03/04/revised PY - 2015/04/23/accepted PY - 2015/7/22/entrez PY - 2015/7/22/pubmed PY - 2016/4/12/medline KW - AD biomarker signature KW - Alzheimer's disease KW - Amyloid phenotyping KW - Clinical trial biomarkers KW - Data-sharing KW - Tau imaging KW - Worldwide ADNI SP - 865 EP - 84 JF - Alzheimer's & dementia : the journal of the Alzheimer's Association JO - Alzheimers Dement VL - 11 IS - 7 N2 - INTRODUCTION: The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. METHODS: We searched for ADNI publications using established methods. RESULTS: ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. DISCUSSION: ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials. SN - 1552-5279 UR - https://www.unboundmedicine.com/medline/citation/26194320/Impact_of_the_Alzheimer's_Disease_Neuroimaging_Initiative_2004_to_2014_ DB - PRIME DP - Unbound Medicine ER -